CEO International Kidney Cancer Coalition Duivendrecht, Noord-Holland, Netherlands
Background: Given limitations of current tools, an unmet need for non-invasive imaging modality for clear cell renal cell carcinoma diagnosis and characterization exists. Results from ZIRCON trial (NCT03849118) suggest 89Zr-girentuximab PET/CT has potential to meet this need. To better elucidate its potential role and understand the patient pathway, a leading group of patient advocates convened. We present on preliminary consensus outcomes.
Methods: Two sessions (1 live, 1 virtual) with 11 leading kidney cancer patient advocates met with objectives to 1) identify gaps in the patient pathway from diagnosis to treatment, including service delivery, quality of life, education, and awareness.; and 2) provide feedback on real-world utility / implementation of 89Zr-girenuximab PET/CT including administration (requires 2 visits - 1 for administration, 1 for imaging) and educational needs.
Results: The panel agreed on utility for detection, characterization, and differentiation of ccRCC from other renal and metastatic lesions, which informs treatment decisions and minimizes over- and undertreatment. The panel agreed that the 2-visit requirement was advantageous, providing scheduling flexibility and clinical benefit with delayed imaging allowing uptake in small lesions. Patient education on the novel mechanism of action of the targeting agent girentuximab coupled with 89Zr was identified as a priority. Radionuclide therapy, which will be explored in future trials, was also identified as a top interest.
Conclusions: 89Zr-girentuximab is a novel PET/CT imaging agent that may help meet unmet needs of patients. Genuine engagement with leading kidney cancer patient advocates is vital throughout drug development and implementation. Future opportunities for collaboration include guideline and publication review and authorship, focus groups to collect real world evidence from newly diagnosed ccRCC patients and development of education materials.
